Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Inventory (2018 - 2025)

Coherus Oncology's Inventory history spans 8 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Inventory fell 24.6% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, down 24.6%, while the annual FY2025 figure was $3.2 million, 24.6% down from the prior year.
  • Inventory for Q4 2025 was $3.2 million at Coherus Oncology, up from $2.0 million in the prior quarter.
  • Across five years, Inventory topped out at $62.6 million in Q4 2023 and bottomed at $2.0 million in Q3 2025.
  • The 5-year median for Inventory is $37.6 million (2021), against an average of $29.3 million.
  • The largest annual shift saw Inventory soared 61.39% in 2023 before it tumbled 95.7% in 2025.
  • A 5-year view of Inventory shows it stood at $37.6 million in 2021, then increased by 3.05% to $38.8 million in 2022, then skyrocketed by 61.39% to $62.6 million in 2023, then tumbled by 93.28% to $4.2 million in 2024, then decreased by 24.6% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Inventory are $3.2 million (Q4 2025), $2.0 million (Q3 2025), and $4.5 million (Q2 2025).